Last reviewed · How we verify

NCT03366077

Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection in Adult Women

Completed NA Results posted Last updated 15 September 2025
What this trial tests

NA trial testing Probiotic in Recurrent Urinary Tract Infection in Adult Women in 140 participants. Completed in 12 July 2019.

Timeline
13 December 2017
Primary endpoint
12 July 2019
12 July 2019

Quick facts

Lead sponsorBioGaia AB
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment140
Start date13 December 2017
Primary completion12 July 2019
Estimated completion12 July 2019
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

BioGaia AB — full company profile →

Who can join

Adults 18 to 50, female only, with Recurrent Urinary Tract Infection in Adult Women. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. Primary · 6 months

Mean number (Standard Deviation) of confirmed UTIs in adult women with recurrent UTI, during six months from start of intervention, as compared to placebo.

GroupValue95% CI
Active1.2± 1.4
Placebo1.3± 1.3

Adverse events — posted to ClinicalTrials.gov

Time frame: 6 months. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Active
Serious: 0/70 (0%)
Deaths: 0/70
Placebo
Serious: 3/69 (4%)
Deaths: 0/69

Serious adverse events (3 terms)

ReactionSystemActivePlacebo
ConcussionInjury, poisoning and procedural complications
Spontaneous miscarriagePregnancy, puerperium and perinatal conditions
EndometritisInfections and infestations
Other adverse events (43 terms — click to expand)

ReactionSystemActivePlacebo
NasopharyngitisInfections and infestations
HeadacheNervous system disorders
PyrexiaGeneral disorders
MigraineNervous system disorders
DiarrheaGastrointestinal disorders
vulvovaginal candidiasisInfections and infestations
GastroenteritisGastrointestinal disorders
Vulvovaginal mycotic infectionInfections and infestations
DysmenorrheaReproductive system and breast disorders
Conjunctivitis allergicEye disorders
Dust AllergyImmune system disorders
ToothacheGastrointestinal disorders
Seasonal allergyImmune system disorders
Urine odour abnormalRenal and urinary disorders
CoughRespiratory, thoracic and mediastinal disorders
Procedural painInjury, poisoning and procedural complications
Worsening post surgical painGeneral disorders
abdominal pain upperGastrointestinal disorders
InfluenzaInfections and infestations
abdominal distensionGastrointestinal disorders
radius fractureInjury, poisoning and procedural complications
SinusitisInfections and infestations
Ligament sprainInjury, poisoning and procedural complications
TonsillitisInfections and infestations
Toe infectionInfections and infestations
head injuryInjury, poisoning and procedural complications
PneumoniaInfections and infestations
HypertensionVascular disorders
Vaginosis bacterialInfections and infestations
BorreliaInfections and infestations
blood thyroid stimulating hormone increasedEndocrine disorders
Vaginal DischargeReproductive system and breast disorders
musculosceletal painMusculoskeletal and connective tissue disorders
nasal congestionRespiratory, thoracic and mediastinal disorders
Skin infectionInfections and infestations
Abdominal PainGastrointestinal disorders
abortion spontaneousReproductive system and breast disorders
RashSkin and subcutaneous tissue disorders
dysfunctional uterine bleedingReproductive system and breast disorders
EndometritisReproductive system and breast disorders

Most-reported serious reactions: Concussion, Spontaneous miscarriage, Endometritis.

Data from ClinicalTrials.gov NCT03366077 adverse events section.

Sponsor's own description

Urinary tract infections (UTIs) are the most common bacterial infections in women, with about 50% of women experiencing at least one UTI in their lifetime. The main pharmacological treatments of cystitis usually involve the use of antibiotics, in particular quinolones (such as ciprofloxacin and levofloxacin), fosfomycin, second-generation and third-generation cephalosporins, and b-lactam antibiotics associated with b-lactamase inhibitors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Probiotic

Trials testing the same drug.

Other BioGaia AB trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03366077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing